Blurbs

Analysts’ Top Healthcare Picks: Qiagen (QGEN), Oyster Point Pharma (OYST)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Qiagen (QGENResearch Report), Oyster Point Pharma (OYSTResearch Report) and Marinus (MRNSResearch Report) with bullish sentiments.

Qiagen (QGEN)

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Qiagen. The company’s shares closed last Thursday at $49.78.

According to TipRanks.com, Friedrichs is a 3-star analyst with an average return of 2.4% and a 50.0% success rate. Friedrichs covers the Healthcare sector, focusing on stocks such as Siemens Healthineers AG, Babylon, and Alcon.

Currently, the analyst consensus on Qiagen is a Moderate Buy with an average price target of $48.09, which is a -4.3% downside from current levels. In a report issued on July 28, J.P. Morgan also maintained a Buy rating on the stock.

See the top stocks recommended by analysts >>

Oyster Point Pharma (OYST)

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Oyster Point Pharma, with a price target of $20.00. The company’s shares closed last Thursday at $7.96.

According to TipRanks.com, Caufield is a 4-star analyst with an average return of 21.2% and a 55.0% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Aldeyra Therapeutics, Ocuphire Pharma, and IVERIC bio.

Oyster Point Pharma has an analyst consensus of Strong Buy, with a price target consensus of $21.00, which is a 154.5% upside from current levels. In a report released yesterday, Chardan Capital also initiated coverage with a Buy rating on the stock with a $22.00 price target.

Marinus (MRNS)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Marinus, with a price target of $17.00. The company’s shares closed last Thursday at $5.77.

According to TipRanks.com, Higgins is a 4-star analyst with an average return of 5.0% and a 31.5% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals.

Marinus has an analyst consensus of Strong Buy, with a price target consensus of $29.60, representing a 393.3% upside. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $22.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on QGEN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos